Previous 10 | Next 10 |
MediciNova (MNOV) +52% on positive MN-166 data.Raven Industries (RAVN) +50% on being acquired by CNHI for $58.0 per share.Torchlight Energy Resources (TRCH) +39% after update on proposed business combination timing and date for preferred dividend.Hennessy Capital Investment Cor...
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...
Clover Health Investments (CLOV) +37%.Aytu Biopharma (AYTU) +20%.NextDecade Corporation NEXT +20% after Morgan Stanley upgrades on Rio Grande LNG outlook.Cyclerion Therapeutics (CYCN) +16%.The Wendy's (WEN) +16%.Stitch Fix SFIX +14% on Q3 results.PDS Biotechnology PDS...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We’re starting off our coverage today with a look at the biggest pre-market stock movers for Tuesday. Source: Eric Urquhart/Shutterstock.com Before we get to that, let’s take a m...
ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer, will present at two upco...
Aytu Biopharma, Inc. (AYTU) Q3 2021 Earnings Conference Call May 17, 2021 04:30 PM ET Company Participants Joshua Disbrow - Chairman and CEO Richard Eisenstadt - CFO Conference Call Participants Jennifer Kim - Cantor Fitzgerald Presentation Operator Good afternoon and thank you for joining us...
Aytu BioScience (AYTU): Q3 GAAP EPS of -$1.41 misses by $1.08.Revenue of $13.48M (+64.4% Y/Y) misses by $0.56M.Shares -5.9%.Press Release For further details see: Aytu BioScience EPS misses by $1.08, misses on revenue
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline - ...
ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that in vitro data related to the ultraviolet (UV) A light used in the Healight...
ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday, May 17, 2021, at ...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...